We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Curious about Heron Therapeutics (HRTX) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Read MoreHide Full Article
In its upcoming report, Heron Therapeutics (HRTX - Free Report) is predicted by Wall Street analysts to post quarterly loss of $0.15 per share, reflecting an increase of 11.8% compared to the same period last year. Revenues are forecasted to be $30.98 million, representing a year-over-year increase of 3.2%.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Given this perspective, it's time to examine the average forecasts of specific Heron Therapeutics metrics that are routinely monitored and predicted by Wall Street analysts.
According to the collective judgment of analysts, 'Product sales- Sustol' should come in at $3.44 million. The estimate indicates a change of +14.6% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Product sales- Zynrelef' of $4.45 million. The estimate suggests a change of +14.1% year over year.
Analysts expect 'Product sales- Cinvanti' to come in at $22.65 million. The estimate suggests a change of -2% year over year.
Shares of Heron Therapeutics have experienced a change of +9.7% in the past month compared to the +3.2% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), HRTX is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Curious about Heron Therapeutics (HRTX) Q4 Performance? Explore Wall Street Estimates for Key Metrics
In its upcoming report, Heron Therapeutics (HRTX - Free Report) is predicted by Wall Street analysts to post quarterly loss of $0.15 per share, reflecting an increase of 11.8% compared to the same period last year. Revenues are forecasted to be $30.98 million, representing a year-over-year increase of 3.2%.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Given this perspective, it's time to examine the average forecasts of specific Heron Therapeutics metrics that are routinely monitored and predicted by Wall Street analysts.
According to the collective judgment of analysts, 'Product sales- Sustol' should come in at $3.44 million. The estimate indicates a change of +14.6% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Product sales- Zynrelef' of $4.45 million. The estimate suggests a change of +14.1% year over year.
Analysts expect 'Product sales- Cinvanti' to come in at $22.65 million. The estimate suggests a change of -2% year over year.
View all Key Company Metrics for Heron Therapeutics here>>>
Shares of Heron Therapeutics have experienced a change of +9.7% in the past month compared to the +3.2% move of the Zacks S&P 500 composite. With a Zacks Rank #3 (Hold), HRTX is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>